Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 9, Issue 5, 1999, Pages 234-243

  Vigna, G B ^a   Donega, P ^a   Passaro, A ^a   Zanca, R ^a   Cattin, L ^b   Fonda, M ^b   Pauciullo, P ^c   Marotta, G ^c   Fellin, R ^a,e   Gasparrini, S ^d   Piliego, T ^d  

^a Section of Internal Medicine II   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Medical Department   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cholesterol; Chronobiology; Coagulation; Fibrinolysis; Gemflbrozil; Oral fat load; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GEMFIBROZIL; LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ITALY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BLOOD COAGULATION; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; GEMFIBROZIL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ITALY; LIPOPROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTPRANDIAL PERIOD; SIMVASTATIN; TRIGLYCERIDES;

EID: 0033201885     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Patsch JR (1991) Postprandial dyslipidemia and coronary artery disease. Atheroscl Rev 22: 47-49
2. International Task Force for Prevention of Coronary Heart Disease Prevention of coronary heart disease. Scientific background and clinical guidelines 1992. Current Medical Literature Ltd., London, 1992
3. Lopez-Virella M, Stone P, Ellis S, Colwell JA (1985) Cholesterol determination in high density lipoprotein separated by three different methods. Clin Chem 31: 746-750
4. Dagen MM, Packard CJ, Shepherd J (1991) A comparison of commercial kits for the measurement of lipoprotein(a). Ann Clin Biochem 28: 359-364
5. Silberman SR, Armentrout MA, Vella FA, Saha AL (1990) Macra Lp(a) for quantitation of human lipoprotein(a) by enzyme linked immunoassay. Clin Chem 36: 961
6. Utermann G, Hees M, Steinmetz A (1977) Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 269: 604-607
7. Clauss A (1957) Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 17: 237-240
8. Ødegård OR, Lie M, Abilgaard U (1975) Heparin cofactor activity measured with an amidolytic method. Thromb Res 6: 287-294
9. Soria J, Soria C, Samama M (1978) A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. In: Davidson JF, Rowan RM, Samama MM, Desmoyers PC (eds) Progress in Chemical Fibrinolysis and Thrombolysis, 3. Raven Press, New York, pp 337-346
10. Declerck PJ, Alessi MC, Verstreken M, Krulthof EKO, Juhan-Vague J, Collen D (1988) Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71: 220-225
11. Bergsdorf N, Nilsson T, Wallen P (1983) An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 50: 740-744
12. Austin MA, Hokanson JE, Edwards KL (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81(4A): 7B-12B
13. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (1998) Triglyceride concentration and ischernic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 97:1029-1036
14. Barrit DW (1956) Alimentary lipaemia in men with coronary artery disease and in controls. BMJ 2: 640-644
15. Patsch JR, Miesenböck G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM jr, Patsch W (1992) Relation of triglyceride metabolism and coronary artery disease. Study in the postprandial state. Arterioscl Thromb 12:1336-1345
16. Cohn JS (1994) Postprandial lipid metabolism. Curr Opin Lipidol 5: 185-190
17. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60: 473-485
18. Miesenböck G, Patsch JR (1992) Postprandial hyperlipemia: the search for the atherogenic lipoprotein. Curr Opin Lipidol 3: 196-201
19. Mann CJ, Yen FT, Grant AM, Bihain BE (1991) Mechanism of plasma cholesterol ester transfer in hypertriglyceridemia. J Clin Invest 88: 2059-2066
20. 2: relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80: 341-347
21. Attia N, Durlach V, Roche D, Paul JL, Soni T, Zahouani A, Landron F, Labrousse F, Leutenegger M, Girard-Globa A (1998) Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment. Atherosclerosis 141: 307-314
22. Bumett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW (1998) The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler Thromb Vasc Biol 18: 1906-1914
23. Syvänne M, Markkola V, Hilden H, Taskinen MR (1993) Gemfibrozil reduces postprandial lipemia in non-insulin dependent diabetes mellitus. Arterioscler Thromb 13: 286-295
24. Fruchart JC, Brewer HB, Leitersdorf E for the Fibrate Consensus Group (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 81: 912-917
25. Cohen JC, Noakes TD, Spinnler-Benade M (1988) Serum triglyceride responses to fatty meals: effect of meal fat content. Am J Clin Nutr 47: 825-827
26. Karpe F, Bell V, Björken J, Hamsten A (1995) Quantification of post-prandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 15: 199-207
27. Nestel PJ (1964) Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest 43: 943-949
28. Patsch JR, Karlin JB, Scott LW, Gotto AM jr (1983) Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 80: 1449-1453
29. Pfaiffinger D, Schuelke J, Kim C, Fless GM, Scanu AM (1991) Relationship between apo(a) isoforms and Lp(a) density in subjects with different apo(a) phenotype: a study before and after a fatty meal. J Lipid Res 32: 679
30. Kostner GM (1991) Interrelation of Lp(a) with plasma triglycerides. Atheroscl Rev 22: 131-135
31. Andersen P, Smith P, Seljeflot I, Brataker S, Amesen H (1990) Effects of gemfibrozil on lipids and hemostasis after myocardial infarction. Thromb Haemost 63: 174-177
32. Maggi FM, Piglionica MR, DeMichele L, Baroni S, Biasi GM, Catapano AL (1994) Bezafibrate lowers elevated plasma levels of fibrinogen and lipoprotein(a) in patients with type Ila and b dyslipoproteinemia. Nutr Metab Cardiovasc Dis 4: 215-220
33. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A (1993) Effect of three fibrate derivatives and two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemostas 70: 241-243
34. Bröijersen A, Eriksson M, Wilman B, Angelin B, Hjemdahl P (1996) Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 16: 511-516
35. Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ (1992) Gemfibrozil reduces plasma prothrombin fragment Fl+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemosts 67: 503-506
36. Takada A, Takada Y, Urano T (1994) The physiological aspects of fibrinolysis. Thromb Res 76: 1-31
37. Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer Al, Loscalzo J, Williams GH, Muller JE (1992) Effects of platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. Am J Cardiol 70: 1051-1055
38. Akiyama Y, Kazama M, Tahara C, Shimazu C, Otake J, Kamei K, Toshihiko N, Sakurai N, Yasumuro Y, Suzuki S, Maeba E, Nishida T (1990) Reference values of hemostasis related factors of healthy Japanese adults. I: circadian fluctuation. Thromb Res 60: 281-289
39. Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J (1990) Circadian variations in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 7: 203-216
40. Andreotti F, Davies GJ, Hackett DR, Khan MI, DeBart ACW, Aber VR, Maseri A, Kluft C (1988) Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am. J Cardiol 62: 635-637
41. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E (1992) Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 12: 19-27
42. Keber I, Lavre J, Suc S, Keber D (1994) The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates. Fibrinolysis 8: 57-59
43. Avellone G DiGarbo R, Cordova R, Panno AV, Ranelli G, DeSimone R, Bompiani GD (1993) Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis 7: 416-421
44. Avellone G, DiGarbo R, Cordova R, Piliego T, Ranelli G, DeSimone R, Bompiani GD (1995) Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coag Fibrinol 6: 543-548